BTF3 and its role in liver cancer progression
Author Information
Author(s): Kong Minyu, Shi Xiaoyi, Gao Jie, Guo Wenzhi
Primary Institution: The First Affiliated Hospital of Zhengzhou University
Hypothesis
The study investigates the role of BTF3 in hepatocellular carcinoma and its relationship with PDCD2L and the p53 signaling pathway.
Conclusion
BTF3 promotes the progression of hepatocellular carcinoma by upregulating PDCD2L and inhibiting the p53 signaling pathway.
Supporting Evidence
- BTF3 expression was significantly higher in hepatocellular carcinoma tissues compared to normal tissues.
- High BTF3 expression correlated with poor prognosis in patients with hepatocellular carcinoma.
- Knockdown of BTF3 inhibited the proliferation and promoted apoptosis of hepatocellular carcinoma cells.
- BTF3 was found to directly promote the transcription of PDCD2L.
- PDCD2L was shown to promote proliferation and inhibit apoptosis in hepatocellular carcinoma cells.
Takeaway
BTF3 is a protein that helps liver cancer grow by making another protein called PDCD2L work harder, which stops a cancer-fighting protein called p53 from doing its job.
Methodology
The study involved analyzing mRNA and protein expression levels in hepatocellular carcinoma tissues, performing cell function assays, and using various molecular biology techniques to investigate the interactions between BTF3, PDCD2L, and the p53 pathway.
Potential Biases
Potential biases may arise from the selection of cell lines and the specific experimental conditions used.
Limitations
The study primarily focuses on in vitro and in vivo models, which may not fully replicate human disease complexity.
Participant Demographics
Patients with hepatocellular carcinoma, with tissue samples collected from 128 pairs of tumor and normal tissues.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website